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This study aimed to analyze the overall survival period of
adult lymphoblastic lymphoma patients treated with various
therapeutic regimens, and to assess the determinants affecting
survival outcome. Twenty-five adult patients with lympho-
blastic lymphoma who had been treated at Severance Hospital,
Yonsei University College of Medicine, Seoul, Korea from
June 1996 to June 2005 were analyzed retrospectively. As an
initial remission induction chemotherapy, the hyper-CVAD
regimen was performed in eight patients, the Stanford/Nor-
thern California Oncology Group (NCOG) regimen in five, the
CAVOP regimen in four, the m-BACOP regimen in three, and
the CHOP regimen in one patient. Patients were divided into
two groups according to their therapeutic modalities. Twenty
patients received conventional chemotherapy alone and five
received subsequent PBSCT after conventional chemotherapy.
Four patients of the PBSCT group underwent autologous
PBSCT and one underwent allogeneic PBSCT. The overall
response rate was 80% (60% showing a complete response,
20% showing a partial response) and the relapse rate was
73.3%. The overall survival (OS) rate was 55.1% at 1 year,
31.5% at 5 years, and 23.6% at 9 years. The disease-free
survival (DFS) rate was 46.7% at 1 year and 30.0% at 7 years.
The 5-year OS rate in relation to the regimens was 60% with
the Stanford/NCOG regimen, 50% with the CAVOP regimen,
and 33.3% with the m-BACOP regimen. The patients treated
with the hyper-CVAD regimen had an 18.2% 2-year OS rate,
and other patients with CHOP or COPBLAM-V expired early
in their course. The OS rate in patients treated with conven-
tional chemotherapy alone was 19.8%, whereas patients treated
with subsequent PBSCT after chemotherapy showed 50%
overall survival (p = 0.25). The age at presentation influenced
the outcome of the patients (p = 0.01). The Stanford/NCOG
regimen is an effective initial choice of therapy for lympho-
blastic lymphoma patients, and is superior to the hyper-CVAD
regimen in complete response rate and overall survival rate (p
= 0.36). Addition of PBSCT after chemotherapy may be
needed for achieving optimal outcomes.
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INTRODUCTION
Lymphoblastic lymphomas (LL) represent 1.5%
to 4% of all adult non-Hodgkin lymphomas
(NHLs).1-4 These high-grade lymphomas are
usually composed of precursor T cells, commonly
present with mediastinal mass, and have a pre-
dilection for young adults.3,4 LLs are aggressive
compared to other NHLs, frequently involve the
bone marrow and/or central nervous system and
are indistinguishable from acute lymphocytic
leukemia (ALL) in many respects.3,4
Because of the poor prognosis of LL, many
attempts have been made to determine the ade-
quate treatment modality to increase overall sur-
vival rates. The current recommended treatment
modalities include conventional chemotherapy
and peripheral blood stem cell transplantation
(PBSCT) after chemotherapy.
4
While Lymphoma-
like treatment regimens such as the Stanford/
Northern California Oncology Group (NCOG)
protocol had been commonly used for LL to date,
ALL-type chemotherapy regimens such as hyper-
CVAD (hyperfractionated cyclophosphamide, vin-
cristine, adriamycin, dexamethasone) have been
tried for cases with clinical presentation of LL
with ALL in several studies.1,3
In Korea, few studies regarding the long-term
survival outcome of LL with different treatment
modalities have been reported to date. Therefore,
we undertook a retrospective study for the
patients who received either conventional chemo-
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therapy or PBSCT to analyze the overall survival
of adult lymphoblastic lymphoma patients treated
with various treatment regimens, and to assess the
determinants affecting survival outcomes.
MATERIALS AND METHODS
Patients
We reviewed the medical records of patients
with lymphoblastic lymphoma treated in our
hospital from June 1996 to June 2005. Among the
31 cases of lymphoblastic lymphoma patients, our
analysis excluded six cases, who had not received
any kind of treatment or who had not completed
at least one cycle of chemotherapy. Twenty-five
patients were selected for our study.
The other eligibility criteria common to these
patients included a tissue-confirmed diagnosis of
lymphoblastic lymphoma, age of 15 years or
older, any stage according to the Ann Arbor
system, absence of circulating blast cells in the
peripheral blood, and normal renal, hepatic and
cardiac functions, unless directly attributable to
lymphomatous infiltration.
Staging
All patients were staged according to the Ann
Arbor system.5 The staging procedure included
whole computerized tomographic scans (neck,
chest and abdominopelvis), whole body bone
scans, positron emission tomography scans, bilat-
eral bone marrow aspiration and biopsy.
6
Lactate
dehydrogenase (LDH) and albumin levels were
measured. Since LDH cutoff values change with
the method of measurement over time, we used
the LDH index (patient's LDH value/upper LDH
cutoff value) to distinguish normal versus in-
creased values.
7
Performance status was scored by
the Eastern Cooperative Oncology Group (ECOG)
scale and allocated into one of several risk groups
as described by the International Prognostic
Factors Project for NHL.
Treatment and prognosis
The induction regimen for the treatment of
lymphoblastic lymphoma was mostly based on
adriamycin containing various combination che-
motherapy regimens. These included hyper-
CVAD (hyperfractionated cyclophosphamide, vin-
cristine, adriamycin, and dexamethasone), m-
BACOP (methotrexate, bleomycin, adriamycin,
cyclophosphamide, vincristine, and prednisolone),
CAVOP (cyclophosphamide, adriamycin, VP-16,
vincristine, prednisolone), and CHOP (cyclophos-
phamide, adriamycin, vincristine, and predniso-
lone). The Stanford/NCOG protocol was used for
treatment in 5 patients. This protocol consisted of
a four-phase treatment as follows: (1) induction
chemotherapy with cyclophosphamide, doxorubi-
cin, vincristine, prednisolone, and L-asparaginase,
(2) CNS prophylaxis with intrathecal methotrexate
and whole brain irradiation with 2400 cGy, (3)
consolidation chemotherapy with four additional
cycles of the drugs used in the induction phase,
and (4) maintenance therapy with weekly oral
methotrexate and daily 6-mercaptopurine for a
total of 12 months of treatment.2 Other chemother-
apy regimens used were IMVP-16 (ifosphamide,
mesna, methotrexate, etoposide), COPBLAM-V
(cyclophosphamide, vincristine, prednisolone,
bleomycin, adriamycin, procarbazine) and chemo-
therapy regimens used in adolescent lympho-
blastic lymphoma (prednisolone, vincristine, and
asparaginase; prednisolone, vincristine, and adria-
mycin). Five patients received peripheral blood
stem cell transplantation (PBSCT). Of these, four
received autologous PBSCT, and one received
allogeneic PBSCT. One patient who received the
autologous PBSCT experienced a relapse and as
such, underwent an allogeneic PBSCT afterwards.
Response criteria
We defined the therapeutic responses according
to WHO criteria. Complete remission (CR) was
defined as the complete disappearance of all clini-
cal evidence of lymphoma by physical examina-
tion and restaging workup, and complete resolu-
tion of extramedullary disease. Partial response
(PR) was defined as a minimum of a 50% reduc-
tion in the sum products of the greatest tumor
size and its perpendicular diameter of measurable
tumor lesions, persisting for at least 4 weeks. No
response (NR) was defined as stable or progres-
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sive disease. Relapse was defined as disease recur-
rence at any site after achieving CR.6
For all patients with or without peripheral
blood stem cell transplantation, disease-free sur-
vival was defined as the time between confirmed
diagnosis and relapse, and overall survival was
defined as the time from confirmed diagnosis to
death or last follow-up.
Early death was defined as any deaths within
twelve months of diagnosis.
Statistical analysis
The disease-free survival (DFS) and overall sur-
vival (OS) rates were calculated by Kaplan- Meyer
survival plots, and differences between individual
survival curves of various prognostic factors were
compared by the log-rank test. A p-value < 0.05
was considered to be statistically significant. All
calculations were performed using SPSS software,
version 12.0 (SPSS Inc, Chicago, IL, USA).
RESULTS
Patient characteristics
The clinical characteristics of the 25 patients are
given in Table 1. The median age at presentation
was 31.8 years (range, 15 to 72 years). The study
population showed the expected male predomi-
nance, with 84% of patients having a T-cell immu-
nophenotype and 92% having Ann Arbor stage III
or IV disease. According to the IPI risk groupings,
6 patients (24%) had low-risk disease, 13 (52%)
had low/intermediate, 5 (20%) had high/inter-
mediate, and 1 (4%) had high-risk disease. The
initial performance status according to the ECOG
scale was either 0 or 1 in 19 (76%) patients. Eighty
percent of the patients presented with multiple
lymphadenopathy, and 72% had more than one
extranodal involvement. Bone marrow involve-
ment was present in 52% of the patients, but
central nervous system involvement was not
observed in all study groups.
Treatment
The patients were divided into two groups
Table 1. Characteristics of Patients with Lymphoblastic
Lymphoma
Clinical parameters No. (%)
Sex Male 18 (72.0)
Female 7 (28.0)
Stage (Ann Arbor)
I, II 2 (8.0)
III, IV 23 (92.0)
Performance status (ECOG)
< 2 19 (76.0)
2 6 (24.0)
IPI (International Prognostic Index)
Low 6 (24.0)
Low intermediate 13 (52.0)
High intermediate 5 (20.0)
High 1 (4.0)
Immunophenotype
B 4 (16.0)
T 21 (84.0)
B symptom
Absent 11 (44.0)
Present 11 (44.0)
Unspecified 3 (12.0)
Multiple lymphadenopathy
Absent 5 (20.0)
Present 20 (80.0)
Extranodal involvement
1 7 (28.0)
> 1 18 (72.0)
LDH
upper normal limit 13 (52.0)
> upper normal limit 12 (48.0)
Albumin
Within normal range 3 (12.0)
Not within normal range 22 (88.0)
BM involvement
Absent 12 (48.0)
Present 13 (52.0)
Treatment
Conventional chemotherapy 20 (80.0)
CTx + PBSCT 5 (20.0)
ECOG, Eastern Cooperative Oncology Group; LDH, lactate
dehydrogenase; CTx, chemotherapy; PBSCT, peripheral blood
stem cell transplantation; BM, bone marrow.
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(conventional chemotherapy versus chemotherapy
plus PBSCT) according to the therapeutic moda-
lities they received, as listed in Table 2. Twenty
patients (80%) received conventional chemo-
therapy alone and five (20%) received subsequent
PBSCT after chemotherapy. Among the PBSCT
group, four patients underwent autologous
PBSCT, while one underwent allogeneic PBSCT.
One patient who received autologous PBSCT
experienced a recurrence 57 months later, and
subsequently received allogeneic PBSCT (included
in the autologous PBSCT group).
The initial regimens of chemotherapy are listed
in Table 3. Eight patients received the hyper-
CVAD regimen, five received the Stanford/NCOG
regimen, four received the CAVOP regimen, three
received the m-BACOP regimen, and one received
the CHOP regimen. The remaining patients re-
ceived a variety of other regimens, including
IMVP-16 (ifosphamide, mesna, methotrexate,
etoposide), COPBLAM-V (cyclophosphamide, vin-
cristine, prednisolone, bleomycin, adriamycin,
procarbazine), and chemotherapy regimens used
in adolescent lymphoblastic lymphoma (predniso-
lone, vincristine, and asparaginase, prednisolone,
vincristine, and adriamycin).
Response and outcomes
Of the 25 patients for which treatment could be
assessed, 20 responded to induction therapy for
an overall response rate of 80% (complete res-
ponse, 60%; partial response, 20%). The relapse
rate was 73.3% (Table 4). With a median follow-up
period of 15 months for surviving patients, overall
survival was 55.1% at 1 year, 31.5% at 5 years, and
23.6% at 9 years (Fig. 1). The one-year disease-free
survival (DFS) rate was 46.7%, and the 7-year DFS
was 30.0% (Fig. 2).
The 5-year overall survival rates for various
initial chemotherapy regimens as shown in Fig. 3
were 60% with the Stanford/NCOG regimen, 50%
with the CAVOP regimen, 33.3% with the m-Table 3. Initial Regimens of Chemotherapy
Regimen No. (%)
Hyper-CVAD 8 (32)
Stanford/NCOG 5 (20)
CAVOP 4 (16)
m-BACOP 3 (12)
CHOP 1 (4)
IMVP-16 1 (4)
COPBLAM-V 1 (4)
Others 2 (8)
Total 25 (100)
Hyper-CVAD, hyperfractionated cyclophosphamide, vincristine,
adriamycin, and dexamethasone; Stanford/NCOG, Stanford/
Northern California Oncology Group; CAVOP, cyclophospha-
mide, adriamycin, etoposide, vincristine, and prednisolone; m-
BACOP, methotrexate, bleomycin, adriamycin, cyclophospha-
mide, vincristine, and prednisolone; CHOP, cyclophosphamide,
adriamycin, vincristine, and prednisolone; IMVP-16, ifospha-
mide, mesna, methotrexate, and etoposide; COPBLAM-IV, cyclo-
phosphamide, vincristine, prednisolone, bleomycin, adriamycin,
and procarbazine; Others: prednisolone, vincristine, and aspara-
ginase; asparaginase, prednisolone, vincristine, and adriamycin.
Table 2. Therapeutic Modalities
Treatment No. (%)
Chemotherapy group 20 (80)
Chemotherapy + PBSCT group 5 (20)
autologous PBSCT 4 (80)
allogeneic PBSCT 1 (20)
Total 25 (100)
PBSCT, peripheral blood stem cell transplantation.
Fig. 1. Overall survival rate (solid line) and disease-free
survival rate (dashed line) in twenty-five lymphoblastic
lymphoma patients.
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BACOP regimen, and 18.2% with the hyper-
CVAD regimen Patients treated with other regi-
mens including CHOP and COPBLAM-V expired
early in their course.
The overall survival rates with conventional
chemotherapy and chemotherapy plus PBSCT are
depicted in Fig. 4. Overall survival in patients
treated with conventional chemotherapy alone
was 19.8% at 8 years, whereas patients treated
with chemotherapy plus PBSCT showed 50%
overall survival at 9 years. The chemotherapy plus
PBSCT group showed a higher response rate, but
without statistical significance (p = 0.25).
Causes of death
Of twenty-five lymphoblastic lymphoma patients,
seventeen patients (68%) expired, seven from
infection (sepsis, 57.1%; pneumonia 42.9%), and
three as a result of disease progression (Table 5).
One patient expired from organ failure, and one
Table 4. Treatment Response
Regimen
CR PR NR Relapse rate
No. (%) No. (%) No. (%) No. (%)
Stanford/NCOG 4 (80.0) 1 (20.0) 0 (0.0) 3 (60.0)
Hyper-CVAD 4 (50.0) 4 (50.0) 0 (0.0) 3 (37.5)
Others 7 (58.3) 0 (0.0) 5 (41.7) 5 (41.7)
Total 15 (60.0) 5 (20.0) 5 (20.0) 11 (73.3)
CR, complete response; PR, partial response; NR, no response; Stanford/NCOG, Stanford/Northern California Oncology Group;
Hyper-CVAD, hyperfractionated cyclophosphamide, vincristine, adriamycin, and dexamethasone.
Fig. 2. Overall survival rate in twenty-five lymphoblastic
lymphoma patients treated with various induction
regimens.
Fig. 3. Overall survival rate in twenty patients treated
with conventional chemotherapy alone (solid line) and
five patients with subsequent PBSCT after chemotherapy
(dashed line).
Table 5. Causes of Death
Cause of death No. (%)
Infection 7 (41.2)
Sepsis 4 (57.1)
Pneumonia 3 (42.9)
Disease progression 3 (17.6)
Organ failure 1 (5.9)
Acute myocardial infarction 1 (5.9)
Unspecified 5 (29.4)
Total 17 (100.0)
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from acute myocardial infarction. Of the seven-
teen expired patients, eleven (64.7%) suffered
early deaths, four from infection (sepsis, two
patients; pneumonia, two patients), two from
disease progression, one from organ failure, and
four from unspecified causes.
Prognosis
We compiled information on the prognostic
factors (age at presentation, performance status,
serum LDH level, Ann Arbor stage, presence of
multiple lymphadenopathy, and number of ex-
tranodal involvements) associated with the out-
comes of these 25 patients to identify independent
prognostic factors. In order to select potential
prognostic factors, we performed a series of uni-
variate analysis.
The associations between each presenting char-
acteristic and complete response rate, disease-free
survival rate, and overall survival rate are listed
in Table 6. Old age was a significant prognostic
factor associated with a poor overall survival rate
(p = 0.01), but was not a significant factor for CR
or DFS. Other clinical parameters such as sex, Ann
Arbor stage, performance status (ECOG), IPI, im-
munophenotype, presence of B symptom, mul-
tiple lymphadenopathy, extranodal involvement,
LDH index, bone marrow involvement, albumin
level, and treatment modality were not statisti-
cally significant factors for CR, DFS, or OS.
DISCUSSION
Most of the LL patients in this study were
young individuals who frequently manifested
with stage III or IV (92%), T-cell type (84%), cer-
vical lymphadenopathy (52%), bone marrow in-
volvement (52%), and a mediastinal mass (36%)
upon initial diagnosis. These findings were the
same as those reported by other studies done in
Western as well as Asian countries, demonstrating
the similarity in clinical characteristics of lym-
phoblastic lymphoma among different ethnic
groups.3,4
In general, it is recommended that lympho-
blastic lymphoma in adults be approached and
treated in a manner similar to that for ALL.1
Various adult LL treatment protocols have been
presented which are similar to that used in ALL
treatment. Both the Stanford/NCOG and hyper-
CVAD regimens are well known ALL chemo-
therapy regimens, but are also used in treating
lymphoblastic lymphoma. The complete response
(CR) rate and disease-free survival (DFS) rate
obtained with the Stanford/NCOG regimen was
80% and 60% respectively, which was comparable
to results previously reported in other studies.6,8-10
However, the CR and DFS rates obtained with the
hyper-CVAD regimen were 50% and 31.3%, res-
pectively, which were lower than those reported
in other studies.3,8 In our study, the overall sur-
vival rate was 60% at 9 years with the Stanford/
NCOG regimen (Fig. 3) and only 18.2% at 2 years
with the hyper-CVAD regimen, showing it to be
inferior to those treated with the Standford/
NCOG regimen. In contrast, Thomas et al. re-
ported that the estimates for 3-year progression-
free and overall survival for 33 lymphoblastic
lymphoma patients treated with the hyper-CVAD
regimen were 66% and 70%, respectively.3 Al-
though the hyper-CVAD regimen had become one
of the promising chemotherapy regimens in
therapy of lymphoblastic lymphoma, it did not
show superior results compared to other regimens
in our study. The work of Y.C. Chen8 supports
our results which suggest that the Stanford/
NCOG regimen may be a more effective initial
choice of therapy than the hyper-CVAD regimen
for lymphoblastic lymphoma.
Peripheral blood stem cell transplantation
(PBSCT) is an option for some patients with
lymphoblastic lymphoma, particularly those with
recurrent or refractory disease.
9
Previous studies
showed a better survival outcome for a hemato-
poietic stem cell transplantation group compared
with those who received conventional chemo-
therapy.9,11 In our present work, the overall sur-
vival rate was 50% in the PBSCT group and 19.8%
in the conventional chemotherapy group after 8
years (Fig. 4). Although the difference in overall
survival rate between the chemotherapy plus
PBSCT group and the conventional chemotherapy
group was statistically insignificant (p = 0.46), a
tendency toward a higher survival rate in the
PBSCT group was observed, consistent with
previous reports.
Table 6. Univariate Analysis of Patient Characteristics
Clinical parameters
CR DFS OS
% p value % p value % p value
Age (year) 0.1705 0.1305 0.0095
60 50.0 0.0 25.7
> 60 60.9 34.8 0.0
Sex 0.1895 0.0988 0.2734
Male 50.0 22.2 15.1
Female 85.7 57.1 57.1
Stage (Ann Arbor) 0.2406 0.2731 0.3069
I, II 100.0 50.0 0.0
III, IV 56.5 30.4 24.5
Performance status (ECOG) 0.4504 0.9916 0.9978
0 or 1 63.2 31.6 15.0
2 50.0 33.3 33.3
International prognostic index 0.7789 0.2718 0.2822
Low 66.7 16.7 0.0
Low intermediate 53.9 23.1 20.5
High intermediate 60.0 80.0 66.7
High 100.0 0.0 0.0
Immunophenotype 0.1758 0.4023 0.6612
B cell 66.7 25.0 25.0
T cell 25.0 33.3 24.4
B symptom 0.8024 0.5836 0.6559
Absent 63.6 27.3 17.1
Present 54.6 27.3 21.2
Multiple lymphadenopathy 0.3651 0.9917 0.9056
Absent 40.0 40.0 40.0
Present 65.0 30.0 22.1
Extranodal involvement 0.5548 0.1162 0.0896
1 57.1 14.3 14.3
> 1 61.1 38.9 28.8
LDH index 0.8322 0.3717 0.8507
normal upper limit 53.9 23.1 20.5
> normal upper limit 66.7 41.7 34.3
Bone marrow involvement 0.9395 0.9174 0.9699
Absent 58.3 33.3 0.0
Present 61.5 30.8 30.8
Albumin 0.7748 0.5722 0.6804
Within normal range 59.1 31.8 25.6
Not within normal range 66.7 33.3 0.0
Treatment 0.2293 0.5362 0.3252
Conventional chemotherapy 55.0 30.0 19.8
CTx + PBSCT 80.0 40.0 40.0
CR, complete response; DFS, disease-free survival; OS, overall survival; ECOG, Eastern Cooperative Oncology Group; LDH, lactate
dehydrogenase; CTx, chemotherapy; PBSCT, peripheral blood stem cell transplantation.
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Several studies have compared the overall sur-
vival and relapse rates of autologous and allo-
geneic transplantation for non-Hodgkin's lym-
phoma. Levine et al. reported overall survival
rates comparable to those in our study for both
autologous (56%) and allogeneic transplant
recipients (80%), regardless of disease stage, bone
marrow involvement, time from diagnosis to
transplantation, or other potentially confounding
factors.9 In another study by Gouill et al., the
analysis of 43 patients with relapsed lympho-
blastic lymphoma revealed a higher continuing
CR rate in patients with allogeneic BMT (50%)
than in patients with autologous PBSCT (14.3%).12
A graft-versus-lymphoma effect may have played
a role in the lower relapse rate following allo-
geneic transplantation.13-15 In our study, one of the
patients treated with autologous PBSCT experi-
enced a recurrence 57 months after the procedure,
and subsequently received an allogeneic PBSCT.
Although the overall survival rate was better in
autologous than allogeneic transplant recipients in
this study (75% vs. 0% at 15 months, respectively),
the number of allogeneic transplant patients were
too small to confirm the significance of these
results.
The mortality rate was 68% in our study, with
infection being the most common cause of deaths
(41.2%). Among these cases of infection, 57.1%
were from sepsis and 42.9% were from pneu-
monia. Eleven patients (64.7%) suffered early
deaths, with infection (35.4%) being the major
cause (sepsis, two patients; pneumonia, two
patients).
The mortality rates for the Stanford/NCOG and
hyper-CVAD regimen groups were 40% and
62.5%, respectively. Infection as a cause of death
was not observed in the Stanford/NCOG group,
however, three of the five patients in the hyper-
CVAD group died from infection (sepsis, two
patients; pneumonia, one patient). It is not known
whether the infection source was endogenous or
exogenous, and further work is needed to eluci-
date the causes of infection and to lower mortality
rates.
The associations between the various presenting
characteristics and complete response rate, di-
sease-free survival rate, and overall survival rate
were analyzed. Old age was a significant factor
associated with the overall survival rate (p = 0.01),
supporting the results of Hahn et al.16 However,
old age was not a significant factor for the
complete response rate or disease-free survival
rate.
Other clinical parameters such as sex, Ann
Arbor stage, performance status (ECOG), IPI,
immunophenotype, presence of B symptom, mul-
tiple lymphadenopathy, extranodal involvement,
LDH index, bone marrow involvement, albumin
level, and treatment modality were insignificant
factors in the complete response rate, disease-free
survival rate, and overall survival rate.
In conclusion, the Stanford/NCOG regimen
may be an effective initial choice of therapy for
lymphoblastic lymphoma patients. Peripheral
blood stem cell transplantation should be man-
dated after achieving complete or partial response
with chemotherapy rather than treatment with
conventional chemotherapy alone in order to
achieve a higher survival outcome. Furthermore,
allogeneic transplantation, when an HLA-identical
sibling is found, could be an option for young
patients in their first CR from a high-risk disease
or for relapsing patients in their second CR.
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